Covid-19: WHO 'strongly advises against' use of two treatments

Two Covid-19 antibody therapies are no longer recommended by the World Health Organization (WHO), because the Omicron variant, and its latest offshoots, have likely rendered them obsolete.

The two therapies — which are designed to work by binding to the spike protein of SARS-CoV-2, in order to neutralise the virus' ability to infect cells — were some of the first medicines developed early on in the pandemic.

The virus has since evolved, and mounting evidence from lab tests suggests that the two therapies — sotrovimab, as well as casirivimab-imdevimab — have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the US health regulator.

On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with Covid-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published in the British Medical Journal.

GSK and partner Vir Biotechnology's sotrovimab — which has generated billions in sales and became one of the British drugmaker's top sellers last year — was pulled off the US market by the US Food and Drug Administration (FDA) in April.

Given the United States had begun to question sotrovimab's clinical effectiveness against Omicron as early as February, the WHO's realisation is coming a little late, said Penny Ward, a visiting professor in pharmaceutical medicine at King's College London.

"Now WHO has issued this recommendation, it will be interesting to see how many other countries align with it," she said.

Regeneron and partner Roche's antibody cocktail casirivimab-imdevimab has also generated billions in sales, and was one of the US drugmaker's top sellers last year.

• Covid-19: WHO says nasal vaccines could prevent infection, transmission